Insurance claims for ketamine

Insurance claims for ketamine are requests submitted to health insurers seeking reimbursement or coverage for medically prescribed ketamine treatments. Most major U.S.

Insurers, including Aetna and Blue Cross Blue Shield, typically deny claims for off-label ketamine use in depression due to FDA non-approval as of 2024. Insurers often require documented failure of at least two standard antidepressants before considering esketamine (Spravato) claims, which the FDA approved in 2019 specifically for treatment-resistant depression.

Patients must provide detailed clinical notes and prior authorization forms when submitting insurance claims for ketamine infusions or nasal sprays. Medicare covers esketamine under Part B if administered in a certified healthcare setting but does not cover intravenous racemic ketamine as of June 2024, according to YourInsurance.info.

Out-of-pocket costs per session can range from $400 to $800 without successful insurance claims, according to data from the American Society of Ketamine Physicians (ASKP). Denied insurance claims frequently cite lack of medical necessity or experimental status, with appeals requiring additional supporting documentation such as psychiatric evaluations and peer-reviewed studies.

Successful insurance claim examples include patients receiving Spravato coverage after meeting insurer criteria like diagnosis confirmation by board-certified psychiatrists and regular follow-up assessments documented over six months.